Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p

Endothelial dysfunction (ED) causes worse prognoses in heart failure (HF) patients treated with cardiac resynchronization therapy (CRTd). ED triggers the downregulation of microRNA-130 (miR-130a-5p), which targets endothelin-1 (ET-1). Thus, we evaluated ED and the response to CRTd by assessing miR-130a-5p and ET-1 serum levels. We designed a prospective multi-center study with a 1-year follow-up to evaluate ED, ET-1, and miR-130a-5p in CRTd patients with ED (ED-CRTd) vs. patients without ED (NED-CRTd). Clinical outcomes were CRTd response, HF hospitalization, cardiac death, and all-cause death. At 1-year follow-up, NED-CRTd (n = 541) vs. ED-CRTd (n = 326) patients showed better clinical statuses, lower serum values of B type natriuretic peptide (BNP: 266.25 ± 10.8 vs. 297.43 ± 16.22 pg/mL; p < 0.05) and ET-1 (4.57 ± 0.17 vs. 5.41 ± 0.24 pmol/L; p < 0.05), and higher values of miR-130a-5p (0.51 ± 0.029 vs. 0.41 ± 0.034 A.U; p < 0.05). Compared with NED-CRTd patients, ED-CRTd patients were less likely to be CRTd responders (189 (58%) vs. 380 (70.2%); p < 0.05) and had higher rates of HF hospitalization (115 (35.3%) vs. 154 (28.5%); p < 0.05) and cardiac deaths (30 (9.2%) vs. 21 (3.9%); p < 0.05). Higher miR-130a-5p levels (HR 1.490, CI 95% [1.014–2.188]) significantly predicted CRTd response; the presence of hypertension (HR 0.818, CI 95% [0.669–0.999]), and displaying higher levels of ET-1 (HR 0.859, CI 98% [0.839–0.979]), lymphocytes (HR 0.820, CI 95% [0.758–0.987]), LVEF (HR 0.876, CI 95% [0.760–0.992]), and ED (HR 0.751, CI 95% [0.624–0.905]) predicted CRTd non-response. Higher serum miR-130a-5p levels (HR 0.332, CI 95% [0.347–0.804]) and use of ARNI (HR 0.319, CI 95% [0.310–0.572]) predicted lower risk of HF hospitalization, whereas hypertension (HR 1.818, CI 95% [1.720–2.907]), higher BNP levels (HR 1.210, CI 95% [1.000–1.401]), and presence of ED (HR 1.905, CI 95% [1.238–2.241]) predicted a higher risk of HF hospitalization. Hence, serum miR-130a-5p could identify different stages of ED and independently predict CRTd response, therefore representing a novel prognostic HF biomarker.

[1]  G. Santulli,et al.  Aprocitentan: New insights , 2022, Frontiers in Cardiovascular Medicine.

[2]  G. Paolisso,et al.  Angiotensin receptor/Neprilysin inhibitor effects in CRTd non-responders: from epigenetic to clinical beside. , 2022, Pharmacological research.

[3]  R. Marfella,et al.  Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry , 2022, Cardiovascular Diabetology.

[4]  G. Santulli,et al.  Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  L. Lund,et al.  Cardiac resynchronization therapy with or without defibrillator in patients with heart failure , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  C. Israel,et al.  2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. , 2021, European heart journal.

[7]  H. Bao,et al.  MiR-130a regulating the biological function of colon cancer by targeting inhibition of PTEN. , 2020, European review for medical and pharmacological sciences.

[8]  Jyun-Yi Du,et al.  miRNA-130a improves cardiac function by down-regulating TNF-α expression in a rat model of heart failure. , 2018, European review for medical and pharmacological sciences.

[9]  G. Paolisso,et al.  Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome , 2018, Front. Physiol..

[10]  G. Paolisso,et al.  Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes , 2017, Cardiovascular Diabetology.

[11]  P. Lawford,et al.  Measures of endothelial dysfunction predict response to cardiac resynchronisation therapy , 2016, Open Heart.

[12]  G. Paolisso,et al.  Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes , 2015, Journal of diabetes research.

[13]  D. Franco,et al.  Negative Fgf8-Bmp2 feed-back is regulated by miR-130 during early cardiac specification. , 2015, Developmental biology.

[14]  W. Kuebler,et al.  The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension* , 2014, The Journal of Biological Chemistry.

[15]  R. Marfella,et al.  Impact of Diabetes Mellitus on the Clinical Response to Cardiac Resynchronization Therapy in Elderly People , 2014, Journal of Cardiovascular Translational Research.

[16]  G. Paolisso,et al.  Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non‐responders , 2013, European journal of heart failure.

[17]  F. Romeo,et al.  Endothelial dysfunction is a marker of systemic response to the cardiac resynchronization therapy in heart failure. , 2013, Journal of cardiac failure.

[18]  M. Rudin,et al.  Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure: Role for Impaired In Vivo Neovascularization and Cardiac Repair Capacity , 2012, Circulation.

[19]  Thor Edvardsen,et al.  Increased Levels of Inflammatory Cytokines and Endothelin-1 in Alveolar Macrophages from Patients with Chronic Heart Failure , 2012, PloS one.

[20]  P. Ponikowski,et al.  Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1 , 2011, PloS one.

[21]  N. Varma,et al.  Endothelial dysfunction in heart failure identifies responders to cardiac resynchronization therapy. , 2008, Heart rhythm.

[22]  M. Iglarz,et al.  Mechanisms of ET-1-induced Endothelial Dysfunction , 2007, Journal of cardiovascular pharmacology.

[23]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[24]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[25]  D. Giannessi,et al.  The role of endothelins and their receptors in heart failure. , 2001, Pharmacological research.